•EyeDock debuts AI clinical assistant for ECPs•Report: Rural residents face steep gap in retina care access•FDA grants Orphan Drug designation to Octant's RP oral therapy•Leadership watch: LENZ, CooperCompanies CEOs step down, among exec changes•Roivant, Priovant report positive phase 3 NIU data for brepocitinib•EyeDock debuts AI clinical assistant for ECPs•Report: Rural residents face steep gap in retina care access•FDA grants Orphan Drug designation to Octant's RP oral therapy•Leadership watch: LENZ, CooperCompanies CEOs step down, among exec changes•Roivant, Priovant report positive phase 3 NIU data for brepocitinib
HEADLINES
FEATURED
Exclusive licensing agreement also extends up to four retinal biologics.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
